BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16335926)

  • 1. Effects of variable docking conditions and scoring functions on corresponding protein-aligned comparative molecular field analysis models constructed from diverse human protein tyrosine phosphatase 1B inhibitors.
    Taha MO; AlDamen MA
    J Med Chem; 2005 Dec; 48(25):8016-34. PubMed ID: 16335926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining docking, scoring and molecular field analyses to probe influenza neuraminidase-ligand interactions.
    Abu Hammad AM; Afifi FU; Taha MO
    J Mol Graph Model; 2007 Sep; 26(2):443-56. PubMed ID: 17360207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking and 3D-QSAR on 2-(oxalylamino) benzoic acid and its analogues as protein tyrosine phosphatase 1B inhibitors.
    Zhou M; Ji M
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5521-5. PubMed ID: 16230012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homology modeling of MCH1 receptor and validation by docking/scoring and protein-aligned CoMFA.
    Abu-Hammad A; Zalloum WA; Zalloum H; Abu-Sheikha G; Taha MO
    Eur J Med Chem; 2009 Jun; 44(6):2583-96. PubMed ID: 19250717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.
    Taha MO; Bustanji Y; Al-Bakri AG; Yousef AM; Zalloum WA; Al-Masri IM; Atallah N
    J Mol Graph Model; 2007 Mar; 25(6):870-84. PubMed ID: 17035054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
    Hu X; Stebbins CE
    Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
    Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
    Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building predictive models for protein tyrosine phosphatase 1B inhibitors based on discriminating structural features by reassembling medicinal chemistry building blocks.
    Yang C; Cross K; Myatt GJ; Blower PE; Rathman JF
    J Med Chem; 2004 Nov; 47(24):5984-94. PubMed ID: 15537353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple active site corrections for docking and virtual screening.
    Vigers GP; Rizzi JP
    J Med Chem; 2004 Jan; 47(1):80-9. PubMed ID: 14695822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA.
    Akula N; Lecanu L; Greeson J; Papadopoulos V
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6277-80. PubMed ID: 17049234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques.
    Wei HY; Tsai KC; Lin TH
    J Chem Inf Model; 2005; 45(5):1343-51. PubMed ID: 16180911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
    Yi P; Fang X; Qiu M
    Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
    Zhang H; Li H; Ma Q
    J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-induced conformational changes: improved predictions of ligand binding conformations and affinities.
    Frimurer TM; Peters GH; Iversen LF; Andersen HS; Møller NP; Olsen OH
    Biophys J; 2003 Apr; 84(4):2273-81. PubMed ID: 12668436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
    Holder S; Lilly M; Brown ML
    Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
    Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
    Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical assessment of docking programs and scoring functions.
    Warren GL; Andrews CW; Capelli AM; Clarke B; LaLonde J; Lambert MH; Lindvall M; Nevins N; Semus SF; Senger S; Tedesco G; Wall ID; Woolven JM; Peishoff CE; Head MS
    J Med Chem; 2006 Oct; 49(20):5912-31. PubMed ID: 17004707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors.
    Xue CB; Zhang L; Luo WC; Xie XY; Jiang L; Xiao T
    Bioorg Med Chem; 2007 Mar; 15(5):2006-15. PubMed ID: 17258462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.